These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

481 related articles for article (PubMed ID: 21077739)

  • 1. Analysis of genome-wide methylation and gene expression induced by 5-aza-2'-deoxycytidine identifies BCL2L10 as a frequent methylation target in acute myeloid leukemia.
    Fabiani E; Leone G; Giachelia M; D'alo' F; Greco M; Criscuolo M; Guidi F; Rutella S; Hohaus S; Voso MT
    Leuk Lymphoma; 2010 Dec; 51(12):2275-84. PubMed ID: 21077739
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Decitabine induces very early in vivo DNA methylation changes in blasts from patients with acute myeloid leukemia.
    Claus R; Pfeifer D; Almstedt M; Zucknick M; Hackanson B; Plass C; Lübbert M
    Leuk Res; 2013 Feb; 37(2):190-6. PubMed ID: 23158571
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Digging deep into "dirty" drugs - modulation of the methylation machinery.
    Pleyer L; Greil R
    Drug Metab Rev; 2015 May; 47(2):252-79. PubMed ID: 25566693
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genomic impact of transient low-dose decitabine treatment on primary AML cells.
    Klco JM; Spencer DH; Lamprecht TL; Sarkaria SM; Wylie T; Magrini V; Hundal J; Walker J; Varghese N; Erdmann-Gilmore P; Lichti CF; Meyer MR; Townsend RR; Wilson RK; Mardis ER; Ley TJ
    Blood; 2013 Feb; 121(9):1633-43. PubMed ID: 23297133
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypomethylating agents reactivate FOXO3A in acute myeloid leukemia.
    Thépot S; Lainey E; Cluzeau T; Sébert M; Leroy C; Adès L; Tailler M; Galluzzi L; Baran-Marszak F; Roudot H; Eclache V; Gardin C; de Botton S; Auberger P; Fenaux P; Kroemer G; Boehrer S
    Cell Cycle; 2011 Jul; 10(14):2323-30. PubMed ID: 21654193
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Decitabine activates specific caspases downstream of p73 in myeloid leukemia.
    Tamm I; Wagner M; Schmelz K
    Ann Hematol; 2005 Dec; 84 Suppl 1():47-53. PubMed ID: 16193303
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 5-Aza-2'-deoxycytidine induces p21WAF expression by demethylation of p73 leading to p53-independent apoptosis in myeloid leukemia.
    Schmelz K; Wagner M; Dörken B; Tamm I
    Int J Cancer; 2005 May; 114(5):683-95. PubMed ID: 15609309
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genome-wide methylation profiling in decitabine-treated patients with acute myeloid leukemia.
    Yan P; Frankhouser D; Murphy M; Tam HH; Rodriguez B; Curfman J; Trimarchi M; Geyer S; Wu YZ; Whitman SP; Metzeler K; Walker A; Klisovic R; Jacob S; Grever MR; Byrd JC; Bloomfield CD; Garzon R; Blum W; Caligiuri MA; Bundschuh R; Marcucci G
    Blood; 2012 Sep; 120(12):2466-74. PubMed ID: 22786882
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Decitabine has a biphasic effect on natural killer cell viability, phenotype, and function under proliferative conditions.
    Kopp LM; Ray A; Denman CJ; Senyukov VS; Somanchi SS; Zhu S; Lee DA
    Mol Immunol; 2013 Jul; 54(3-4):296-301. PubMed ID: 23328088
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting epigenetic pathways in acute myeloid leukemia and myelodysplastic syndrome: a systematic review of hypomethylating agents trials.
    Yun S; Vincelette ND; Abraham I; Robertson KD; Fernandez-Zapico ME; Patnaik MM
    Clin Epigenetics; 2016; 8():68. PubMed ID: 27307795
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of MLL5 expression on decitabine efficacy and DNA methylation in acute myeloid leukemia.
    Yun H; Damm F; Yap D; Schwarzer A; Chaturvedi A; Jyotsana N; Lübbert M; Bullinger L; Döhner K; Geffers R; Aparicio S; Humphries RK; Ganser A; Heuser M
    Haematologica; 2014 Sep; 99(9):1456-64. PubMed ID: 24895338
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DNA methylation changes after 5-aza-2'-deoxycytidine therapy in patients with leukemia.
    Yang AS; Doshi KD; Choi SW; Mason JB; Mannari RK; Gharybian V; Luna R; Rashid A; Shen L; Estecio MR; Kantarjian HM; Garcia-Manero G; Issa JP
    Cancer Res; 2006 May; 66(10):5495-503. PubMed ID: 16707479
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genome-wide methylation and expression profiling identifies promoter characteristics affecting demethylation-induced gene up-regulation in melanoma.
    Rubinstein JC; Tran N; Ma S; Halaban R; Krauthammer M
    BMC Med Genomics; 2010 Feb; 3():4. PubMed ID: 20144234
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increasing TIMP3 expression by hypomethylating agents diminishes soluble MICA, MICB and ULBP2 shedding in acute myeloid leukemia, facilitating NK cell-mediated immune recognition.
    Raneros AB; Minguela A; Rodriguez RM; Colado E; Bernal T; Anguita E; Mogorron AV; Gil AC; Vidal-Castiñeira JR; Márquez-Kisinousky L; Bulnes PD; Marin AM; Garay MCG; Suarez-Alvarez B; Lopez-Larrea C
    Oncotarget; 2017 May; 8(19):31959-31976. PubMed ID: 28404876
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The C/EBPdelta tumor suppressor is silenced by hypermethylation in acute myeloid leukemia.
    Agrawal S; Hofmann WK; Tidow N; Ehrich M; van den Boom D; Koschmieder S; Berdel WE; Serve H; Müller-Tidow C
    Blood; 2007 May; 109(9):3895-905. PubMed ID: 17234736
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Five-aza-2'-deoxycytidine-induced hypomethylation of cholesterol 25-hydroxylase gene is responsible for cell death of myelodysplasia/leukemia cells.
    Tsujioka T; Yokoi A; Itano Y; Takahashi K; Ouchida M; Okamoto S; Kondo T; Suemori S; Tohyama Y; Tohyama K
    Sci Rep; 2015 Nov; 5():16709. PubMed ID: 26577244
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential TERT promoter methylation and response to 5-aza-2'-deoxycytidine in acute myeloid leukemia cell lines: TERT expression, telomerase activity, telomere length, and cell death.
    Pettigrew KA; Armstrong RN; Colyer HA; Zhang SD; Rea IM; Jones RE; Baird DM; Mills KI
    Genes Chromosomes Cancer; 2012 Aug; 51(8):768-80. PubMed ID: 22517724
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SMG1 acts as a novel potential tumor suppressor with epigenetic inactivation in acute myeloid leukemia.
    Du Y; Lu F; Li P; Ye J; Ji M; Ma D; Ji C
    Int J Mol Sci; 2014 Sep; 15(9):17065-76. PubMed ID: 25257528
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of Global and Gene-Specific DNA Methylation in de Novo or Relapsed Acute Myeloid Leukemia Patients Treated with Decitabine.
    Zhang LY; Yuan YQ; Zhou DM; Wang ZY; Ju SG; Sun Y; Li J; Fu JX
    Asian Pac J Cancer Prev; 2016; 17(1):431-7. PubMed ID: 26838251
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Decitabine (5-Aza-2'-deoxycytidine) decreased DNA methylation and expression of MDR-1 gene in K562/ADM cells.
    Ando T; Nishimura M; Oka Y
    Leukemia; 2000 Nov; 14(11):1915-20. PubMed ID: 11069027
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.